Skip to content
PreclinicalImmuneSubQIntermittent (hit-and-run senolytic protocols)Apoptosis-inducing; human safety unknownPartial data

FOXO4-DRI

FOXO4-D-Retro-Inverso

Synthetic peptide that selectively induces apoptosis in senescent cells by disrupting FOXO4–p53 interaction.

§ 01   Overview

Overview

Synthetic peptide that selectively induces apoptosis in senescent cells by disrupting FOXO4–p53 interaction.

Mouse data from the Demaria lab. No human trials.

§ 02   Mechanism

Mechanism of action

FOXO4-DRI is a D-amino-acid retro-inverso peptide that binds FOXO4 and displaces p53, triggering p53-mediated apoptosis preferentially in senescent cells where FOXO4 is upregulated.

  • 01Senolytic clearance of senescent cells (preclinical)
  • 02Rejuvenation markers in aged mice

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
Not characterized in humans
Route
SubQ
Frequency
Intermittent (hit-and-run senolytic protocols)

§ 04   Evidence

Evidence & research

Preclinical

Mouse data from the Demaria lab. No human trials.

FDA Status

Not FDA-approved.

§ 07   Sourcing

Sourcing & supply

Regulatory status

Research-only, no commercial channel

No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Unknown in humans

Contraindications

None specified.

§ 10   Questions

FOXO4-DRI FAQ

What is FOXO4-DRI?
Synthetic peptide that selectively induces apoptosis in senescent cells by disrupting FOXO4–p53 interaction. FOXO4-DRI is a D-amino-acid retro-inverso peptide that binds FOXO4 and displaces p53, triggering p53-mediated apoptosis preferentially in senescent cells where FOXO4 is upregulated.
What is FOXO4-DRI used for?
Reported uses include senolytic clearance of senescent cells (preclinical) and rejuvenation markers in aged mice. Evidence strength is rated Preclinical — see the evidence section for detail.
How is FOXO4-DRI dosed?
Commonly referenced dosing is Not characterized in humans, typically intermittent (hit-and-run senolytic protocols), administered SubQ. This is educational reference only; consult a licensed clinician before use.
What are the side effects of FOXO4-DRI?
Commonly reported side effects include unknown in humans. This list is not exhaustive.
Is FOXO4-DRI legal?
No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established. FDA status: Not FDA-approved..

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.